B
BRAVEHEART BIO, INC. COMMON STOCK
NASDAQ: BRVE (Braveheart Bio, Inc.)
Last update: 13 minutes ago27.49
0.06 (0.24%)
AIStockmoo Score
0.4
| Analyst Consensus | 0.0 |
| Insider Activity | 3.0 |
| Price Volatility | -1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.0 |
| Average | 0.40 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| AH BIO FUND IV, L.P. | 30.00 | - | 10,232,420 | 306,972,600 |
| ANDERSON MICHELE A. | 30.00 | - | 1,111 | 33,330 |
| CHIMOVITS EREZ | 30.00 | - | 11,072,420 | 332,172,600 |
| FORBION GROWTH OPPORTUNITIES FUND III COOPERATIEF U.A. | 30.00 | - | 20,723,287 | 621,698,610 |
| JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. | 30.00 | - | 7,420,091 | 222,602,730 |
| LUBNER DAVID CHARLES | 30.00 | - | 55,555 | 1,666,650 |
| MALEK DAVID I | 30.00 | - | 4,166 | 124,980 |
| MURDOCH TRAVIS | 30.00 | - | 83,333 | 2,499,990 |
| ORBIMED ADVISORS LLC | 30.00 | - | 11,072,420 | 332,172,600 |
| RICKEY JAMES PAUL | 30.00 | - | 27,777 | 833,310 |
| VIEHBACHER CHRISTOPHER | 30.00 | - | 83,333 | 2,499,990 |
| Aggregate Net Quantity | 60,775,913 | |||
| Aggregate Net Value ($) | 1,823,277,390 | |||
| Aggregate Avg. Buy ($) | 30.00 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| LUBNER DAVID CHARLES | Director | 07 Aug 2026 | Buy (+) | 55,555 | 30.00 | 1,666,650 |
| MURDOCH TRAVIS | Officer | 07 Aug 2026 | Buy (+) | 83,333 | 30.00 | 2,499,990 |
| ANDERSON MICHELE A. | Officer | 07 Aug 2026 | Buy (+) | 1,111 | 30.00 | 33,330 |
| VIEHBACHER CHRISTOPHER | Director | 07 Aug 2026 | Buy (+) | 83,333 | 30.00 | 2,499,990 |
| MALEK DAVID I | Director | 07 Aug 2026 | Buy (+) | 4,166 | 30.00 | 124,980 |
| RICKEY JAMES PAUL | Officer | 07 Aug 2026 | Buy (+) | 27,777 | 30.00 | 833,310 |
| FORBION GROWTH OPPORTUNITIES FUND III COOPERATIEF U.A. | 07 Aug 2026 | Acquired (+) | 9,132,420 | 30.00 | 273,972,600 | |
| FORBION GROWTH OPPORTUNITIES FUND III COOPERATIEF U.A. | 07 Aug 2026 | Acquired (+) | 7,990,867 | 30.00 | 239,726,010 | |
| FORBION GROWTH OPPORTUNITIES FUND III COOPERATIEF U.A. | 07 Aug 2026 | Buy (+) | 1,920,000 | 30.00 | 57,600,000 | |
| FORBION GROWTH OPPORTUNITIES FUND III COOPERATIEF U.A. | 07 Aug 2026 | Buy (+) | 1,680,000 | 30.00 | 50,400,000 | |
| JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. | 07 Aug 2026 | Acquired (+) | 7,420,091 | 30.00 | 222,602,730 | |
| ORBIMED ADVISORS LLC | Director | 07 Aug 2026 | Acquired (+) | 9,132,420 | 30.00 | 273,972,600 |
| ORBIMED ADVISORS LLC | Director | 07 Aug 2026 | Buy (+) | 1,940,000 | 30.00 | 58,200,000 |
| CHIMOVITS EREZ | Director | 07 Aug 2026 | Acquired (+) | 9,132,420 | 30.00 | 273,972,600 |
| CHIMOVITS EREZ | Director | 07 Aug 2026 | Buy (+) | 1,940,000 | 30.00 | 58,200,000 |
| AH BIO FUND IV, L.P. | 07 Aug 2026 | Acquired (+) | 9,132,420 | 30.00 | 273,972,600 | |
| AH BIO FUND IV, L.P. | 07 Aug 2026 | Buy (+) | 1,100,000 | 30.00 | 33,000,000 | |
| Show more | ||||||
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |